Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100000, China
NCT Number: NCT06764862
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Phase 2
Beijing, Beijing Municipality, 100000, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Time frame: day 1 and week 12
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness
Time frame: day 1 and week 12
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness
Time frame: day 1 and week 12
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness
Haisco Pharmaceutical Group Co., Ltd.
Industry
A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Idiopathic Pulmonary Fibrosis
Acronym: IPF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06230822
Idiopathic Pulmonary Fibrosis, Lung Diseases
Beijing, China
View Trial DetailsNCT06335303
Idiopathic Pulmonary Fibrosis, Lung Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT07712952
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Seoul, South Korea
View Trial DetailsNCT07225296
Idiopathic Pulmonary Fibrosis, Lung Diseases
Baltimore, Maryland, United States
View Trial Details